KyungDong Pharm Co., Ltd. will launch the high-dose BPH treatment “Euronal sustained-release tablet 0.4mg” in July 2020.
“Euronal extended-release tablet 0.4mg” is a treatment for urinary disorders caused by benign prostatic hyperplasia (BPH), and is an increased version of Tamsulosin 0.2mg, which was widely used in Korea.
The advantage of “Euronal extended-release tablet 0.4mg” is that it can be prescribed for the first time without insurance reduction. The existing 0.2mg dose raised concerns about insurance cuts when administering 2T to first-time patients, but “Euronal extended-release tablet 0.4mg” can be administered as a first-line medication to first-time patients without such concerns, increasing the range of choices and convenience for prescribers.
Also, in terms of safety, “Euronal extended-release tablet 0.4mg” was not significantly different from 0.2mg.
We hope that “Euronal extended-release tablet 0.4mg” will help improve the symptoms of patients suffering from diseases related to benign prostatic hyperplasia.
♤ Product Information ♤
|
Product Name |
Euronal extended-release tablet 0.4mg |
|
Ingredient content |
Tamsulosin hydrochloride 0.4mg |
|
Indications |
Urination disorder due to benign prostatic hyperplasia |
|
Dosage and usage |
Adults: Take 0.4 mg orally as tamsulosin hydrochloride once a day after a meal. This medicine should be swallowed whole and should not be crushed or chewed. |
|
Reimbursement Prices |
794 won/tablet |
|
Reimbursement Code |
648104510 |
|
Packaging unit |
30 tablets (10 tablets |